
Gateway to Translation Webinar: Medicxi
The “Gateway to Translation” (G2T) webinar series is a joint initiative between the University of Cambridge (Cambridge Academy of Therapeutic Sciences, CATS) and the University of Manchester (Translation Manchester).
The aim of these monthly webinars is to stimulate the translation of research into the clinics by educating academics about trends, technologies and research in the commercial sphere and by facilitating collaborations

Dr de Rubertis Co-founder and Partner at Medicxi
between academia and the medtech, biotech and pharma industry sectors. Recordings from previous webinars are available here.
The November webinar of this series, hosted by Cambridge Academy of Therapeutic Sciences (CATS), was on Wednesday 27th November from 2-3pm (via Zoom). Our guest speaker was Dr Francesco De Rubertis (Co-founder and Partner at Medicxi). Medicxi is a European investment firm focused on the life sciences sector. Dr De Rubertis gave a talk titled “University Spin-Outs: a View from Venture Capital“.
Topic: “University Spin-Outs: a View from Venture Capital”
Guest Speaker: Dr Francesco De Rubertis (Co-founder and Partner at Medicxi)
Date and Time: Wednesday 27th November from 2-3pm
The webinar was chaired by Dr Terry Parlett, Commercialisation Director at Cambridge Enterprise.
Click to learn more about the speaker
Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and implemented. Francesco currently serves on the boards of a number of portfolio companies, including Centessa Pharmaceuticals, Rivus Pharmaceuticals, Levicept, Alys Pharmaceuticals, TOAD Oncology, D3 Bio and Kaerus Biosciences.
Francesco’s prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Vaxcyte (NASDAQ:PCVX), Molecular Partners (SIX:MOLN), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by The Medicines Company) and Versartis (NASDAQ:VSAR).
Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD Molecular Biology from the University of Geneva. He conducted postdoctoral research at the Whitehead Institute at MIT and is a CFA Charterholder.
Watch a recording from the event below:
0 Comments